"RIPping" off Pancreas Cancer's Blockage of Immune Surveillance.
Cancer Discov
; 14(2): 208-210, 2024 Feb 08.
Article
em En
| MEDLINE
| ID: mdl-38327192
ABSTRACT
SUMMARY:
MHC-I downregulation is correlated with immunotherapy resistance in PDAC, but efficient strategies to increase cell-surface MHC-I are still lacking. This study by Sang, Zhou, Chen, Yu, and colleagues identified inhibition of tumor-intrinsic RIPK2 as a pharmacologic target to block the degradation of MHC-I on tumor cells and improved PDAC responses to anti-PD-1 immunotherapy. See related article by Sang et al., p. 326 (1) .
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Imunoterapia
Tipo de estudo:
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Cancer Discov
Ano de publicação:
2024
Tipo de documento:
Article